NCT04862455: NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer |
|
|
| Recruiting | 2 | 60 | US | Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Hypofractionated Radiation Therapy, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy | M.D. Anderson Cancer Center | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 09/26 | 09/26 | | |
NCT05039632: Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies |
|
|
| Recruiting | 1/2 | 40 | US | Hafnium Oxide-containing Nanoparticles NBTXR3, NBTXR3, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm | 02/26 | 02/26 | | |
